2023 Access Conditions DEA 
Veriheal
MARCH 6, 2024
Department of Health and Human Services (HHS) recommended that the Drug Enforcement Agency (DEA) reshedule cannabis as a Schedule III substance in August of 2023. The HSS found strong scientific support regarding cannabis’ medically beneficial effects for conditions like anorexia , nausea, and chronic pain.
Cannabis Law Report
OCTOBER 4, 2021
A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Canna Law Blog
JULY 14, 2023
On July 5, 2023, the FDA and FTC jointly announced six cease and desist letters to alleged delta-8 product makers. You can access the letters here. But, there’s a huge controversy about whether it can be controlled, with agencies like the DEA saying it is. You can read more about that issue here or here.
Canna Law Blog
MARCH 21, 2022
To impose a hemp moratorium, a county must simply declare a state of emergency related to cannabis and notify the Oregon Department of Agriculture ( ODA ) of the declaration and request that the ODA deny issuance of grower licenses in order to alleviate the conditions giving rise to the declaration.
Cannabis Law Report
MAY 29, 2022
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. 9] Experts predict that this therapy could receive full FDA approval as soon as 2023. [10] DEA and the Controlled Substances Act. Under the Controlled Substances Act of 1970, DEA classifies drugs into one of five schedules.
Veriheal
DECEMBER 27, 2022
Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. In light of this, the Drug Enforcement Administration (DEA) has announced its intention to substantially increase the production quota of psychedelics such as LSD, psilocybin, and mescaline due to be studied in 2023. .
Cannabis Law Report
APRIL 21, 2022
Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public . Promising clinical trial results have generated much interest in studying MDMA as a catalyst to therapy for PTSD and related conditions — and an increased demand for pharmaceutical-grade MDMA.
Expert insights. Personalized for you.
62 
Let's personalize your content